You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 11, November 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE AMERICAN SOCIETY FOR HEAD AND NECK SURGERY
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Maintenance Chemotherapy for High-Risk Patients

A Preliminary Report

Jonas T. Johnson, MD; Eugene N. Myers, MD; Charles H. Srodes, MD; David G. Mayernik, MD; Barbara A. Sigler, RN, MNEd; Victor L. Schramm, Jr, MD; Teresa A. Nolan, MD; Robin L. Wagner

Arch Otolaryngol. 1985;111(11):727-729.


Abstract

• A prospectively designed program employing surgery, radiotherapy, and maintenance chemotherapy was initiated for patients with histologic evidence of extracapsular spread of tumor in cervical metastases. Postoperative radiotherapy consisted of 6,000 rad of cobalt 60 administered in 180- to 200-rad fractions. Chemotherapy was initiated two to four weeks following radiotherapy. Methotrexate sodium (250 mg/sq m), fluorouracil (600 mg/sq m), and leucovorin calcium were administered one day per week, two weeks of three, for a total of 18 treatments in six months. Thirty-two patients have been in the therapeutic program. Toxic reaction has been minimal and selflimiting. One patient stopped chemotherapy because of toxic reaction. One patient (3%) was noncompliant. All patients have been followed up for 18 to 33 months. Twenty-one patients remain alive and free of disease (81% determinate survival). This compares with a 36% (9/25) disease-free survival for concurrent controls and 39% survival for historic controls.

(Arch Otolaryngol 1985;111:727-729)



Author Affiliations

From the Department of Otolaryngology, Eye and Ear Hospital of Pittsburgh (Drs Johnson, Myers, and Schramm and Mss Sigler and Wagner), and the Department of Medicine, Presbyterian-University Hospital, University of Pittsburgh School of Medicine (Drs Srodes, Mayernik, and Nolan).


Footnotes

Accepted for publication June 14, 1985.

Read before the American Society for Head and Neck Surgery, Dorado Beach, Puerto Rico, May 7, 1985.

Reprint requests to Department of Otolaryngology, Eye and Ear Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 230 Lothrop St, Pittsburgh, PA 15213 (Dr Johnson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neutropenic Enterocolitis: A New Complication of Head and Neck Cancer Chemotherapy
Petruzzelli et al.
Arch Otolaryngol Head Neck Surg 1990;116:209-211.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.